Autopsy report · NCT06844669

HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy

“Futility”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 1 year 1 month before it stopped.
• 7 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Washington University School of Medicine

Sponsor type

University, hospital or other

Conditions

HER2-positive Breast Cancer; HER2+ Breast Cancer

Interventions

Carvedilol; Empagliflozin

Participants

7

Sites

1

Countries

United States

Trials that died the same way

• Safety of FMT: OpenBiome Outcomes and Longitudinal Follow-up (STOOL) for Recurrent Clostridium Difficile Infection
  “for futility” (81% match in meaning)
• The Effectiveness of Non-Pyrethroid Insecticide-Treated Durable Wall Liners as a Method for Malaria Control in Endemic Rural Tanzania
  “futility ground” (79% match in meaning)
• Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion
  “Assessment for futility” (79% match in meaning)
• Effectiveness of Ranolazine on Reducing Chest Pain in Patients With Blockage But no Stents
  “due to futility” (78% match in meaning)
• Prevention of Unexplained Recurrent Abortion by Enoxaparine
  “Stopped for futility” (75% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.